|
|
||||||||
The Annals of Thoracic Surgery, Vol 55, 1365-1373, Copyright © 1993 by The Society of Thoracic Surgeons
N Martini, MG Kris, BJ Flehinger, RJ Gralla, MS Bains, ME Burt, R Heelan, PM McCormack, KM Pisters and JR Rigas
From 1984 to 1991, 136 patients with histologically confirmed non-small
cell lung cancer and stage IIIa (N2) disease received two to three cycles
of MVP (mitomycin + vindesine or vinblastine + high-dose cisplatin)
chemotherapy. All patients had clinical N2 disease, defined as bulky
mediastinal lymph node metastases or multiple levels of lymph node
involvement in the ipsilateral mediastinum or subcarinal space on chest
roentgenograms, computed tomographic scans, or mediastinoscopy. The overall
major response rate to chemotherapy was 77% (105/136). Thirteen patients
had a complete response and 92 patients had a partial but major response
(> 50%). The overall complete resection rate was 65% (89/136) with a
complete resection rate of 78% (82/105) in patients with a major response
to chemotherapy. There was no histologic evidence of tumor in the resected
specimens of 19 patients. The overall survival was 28% at 3 years and 17%
at 5 years (median, 19 months). For patients who had complete resection,
the median survival was 27 months and the 3- year and 5-year survivals were
41% and 26%, respectively. There were seven treatment-related deaths, five
of which were postoperative deaths. To date, 33 patients, all of whom had
complete resection, have had no recurrence after treatment. These results
demonstrate that (1) preoperative chemotherapy with MVP produces high
response rates in stage IIIa (N2) disease, (2) high complete resection
rates occur after response to chemotherapy, and (3) survival is longest in
patients who have a complete resection after major response to
chemotherapy.
ARTICLES
Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan- Kettering experience with 136 patients
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York.
This article has been cited by other articles:
![]() |
M. P. Rivera, F. C. Detterbeck, M. A. Socinski, D. T. Moore, M. J. Edelman, T. M. Jahan, R. H. Ansari, J. D. Luketich, G. Peng, M. Monberg, et al. Impact of Preoperative Chemotherapy on Pulmonary Function Tests in Resectable Early-Stage Non-small Cell Lung Cancer Chest, June 1, 2009; 135(6): 1588 - 1595. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Garrido, J. L. Gonzalez-Larriba, A. Insa, M. Provencio, A. Torres, D. Isla, J. M. Sanchez, F. Cardenal, M. Domine, J. R. Barcelo, et al. Long-Term Survival Associated With Complete Resection After Induction Chemotherapy in Stage IIIA (N2) and IIIB (T4N0-1) Non Small-Cell Lung Cancer Patients: The Spanish Lung Cancer Group Trial 9901 J. Clin. Oncol., October 20, 2007; 25(30): 4736 - 4742. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Robinson, J. C. Ruckdeschel, H. Wagner Jr, and C. W. Stevens Treatment of Non-small Cell Lung Cancer-Stage IIIA: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 243S - 265S. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. L. Uy, G. Darling, W. Xu, Q.-L. Yi, M. De Perrot, A. F. Pierre, T. K. Waddell, M. R. Johnston, A. Bezjak, F. A. Shepherd, et al. Improved results of induction chemoradiation before surgical intervention for selected patients with stage IIIA-N2 non-small cell lung cancer J. Thorac. Cardiovasc. Surg., July 1, 2007; 134(1): 188 - 193. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. G. Azzoli, M. G. Kris, and D. G. Pfister Cisplatin Versus Carboplatin for Patients With Metastatic Non-Small-Cell Lung Cancer--An Old Rivalry Renewed J Natl Cancer Inst, June 6, 2007; 99(11): 828 - 829. [Full Text] [PDF] |
||||
![]() |
R. P. Petersen, D. Pham, E. M. Toloza, W. R. Burfeind, D. H. Harpole Jr, S. I. Hanish, and T. A. D'Amico Thoracoscopic lobectomy: a safe and effective strategy for patients receiving induction therapy for non-small cell lung cancer. Ann. Thorac. Surg., July 1, 2006; 82(1): 214 - 218. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-i. Takeda, H. Maeda, T. Okada, T. Yamaguchi, M. Nakagawa, S. Yokota, N. Sawabata, and M. Ohta Results of pulmonary resection following neoadjuvant therapy for locally advanced (IIIA-IIIB) lung cancer. Eur. J. Cardiothorac. Surg., July 1, 2006; 30(1): 184 - 189. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Doddoli, F. Barlesi, D. Trousse, S. Robitail, S. Yena, P. Astoul, R. Giudicelli, P. Fuentes, and P. Thomas One hundred consecutive pneumonectomies after induction therapy for non-small cell lung cancer: An uncertain balance between risks and benefits J. Thorac. Cardiovasc. Surg., August 1, 2005; 130(2): 416 - 425. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Pezzetta, R. Stupp, A. Zouhair, L. Guillou, P. Taffe, C. von Briel, T. Krueger, and H.-B. Ris Comparison of neoadjuvant cisplatin-based chemotherapy versus radiochemotherapy followed by resection for stage III (N2) NSCLC Eur. J. Cardiothorac. Surg., June 1, 2005; 27(6): 1092 - 1098. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Port, R. J. Korst, P. C. Lee, M. A. Levin, D. E. Becker, R. Keresztes, and N. K. Altorki Surgical Resection for Residual N2 Disease After Induction Chemotherapy Ann. Thorac. Surg., May 1, 2005; 79(5): 1686 - 1690. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. S. Choi, D.-Y. Oh, J. H. Kwon, S.-I. Kim, S. R. Park, J.-Y. Bak, J. H. Kim, D.-W. Kim, Y. T. Kim, T.-Y. Kim, et al. Paclitaxel/Platinum-based Perioperative Chemotherapy and Surgery in Stage IIIA Non-small Cell Lung Cancer Jpn. J. Clin. Oncol., January 1, 2005; 35(1): 6 - 12. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Lorent, P. De Leyn, Y. Lievens, E. Verbeken, K. Nackaerts, C. Dooms, D. Van Raemdonck, B. Anrys, J. Vansteenkiste, and The Leuven Lung Cancer Group Long-term survival of surgically staged IIIA-N2 non-small-cell lung cancer treated with surgical combined modality approach: analysis of a 7-year prospective experience Ann. Onc., November 1, 2004; 15(11): 1645 - 1653. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Taron, R. Rosell, E. Felip, P. Mendez, J. Souglakos, M. S. Ronco, C. Queralt, J. Majo, J. M. Sanchez, J. J. Sanchez, et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer Hum. Mol. Genet., October 1, 2004; 13(20): 2443 - 2449. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Guggino, C. Doddoli, F. Barlesi, P. Acri, B. Chetaille, P. Thomas, R. Giudicelli, and P. Fuentes Completion pneumonectomy in cancer patients: experience with 55 cases Eur. J. Cardiothorac. Surg., March 1, 2004; 25(3): 449 - 455. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Trodella, P. Granone, S. Valente, S. Margaritora, G. Macis, A. Cesario, R. M. D'Angelillo, V. Valentini, G. M. Corbo, V. Porziella, et al. Neoadjuvant concurrent radiochemotherapy in locally advanced (IIIA-IIIB) non-small-cell lung cancer: long-term results according to downstaging Ann. Onc., March 1, 2004; 15(3): 389 - 398. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Port, M. S. Kent, R. J. Korst, R. Keresztes, M. A. Levin, and N. K. Altorki Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer Ann. Thorac. Surg., January 1, 2004; 77(1): 254 - 259. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. K. Ferguson Optimal management when unsuspected N2 nodal disease is identified during thoracotomy for lung cancer: cost-effectiveness analysis J. Thorac. Cardiovasc. Surg., December 1, 2003; 126(6): 1935 - 1942. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. V. Scagliotti, R. Fossati, V. Torri, L. Crino, G. Giaccone, G. Silvano, M. Martelli, M. Clerici, F. Cognetti, and M. Tonato Randomized Study of Adjuvant Chemotherapy for Completely Resected Stage I, II, or IIIA Non-Small-Cell Lung Cancer J Natl Cancer Inst, October 1, 2003; 95(19): 1453 - 1461. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. C. Betticher, S.-F. Hsu Schmitz, M. Totsch, E. Hansen, C. Joss, C. von Briel, R. A. Schmid, M. Pless, J. Habicht, A. D. Roth, et al. Mediastinal Lymph Node Clearance After Docetaxel-Cisplatin Neoadjuvant Chemotherapy Is Prognostic of Survival in Patients With Stage IIIA pN2 Non-Small-Cell Lung Cancer: A Multicenter Phase II Trial J. Clin. Oncol., May 1, 2003; 21(9): 1752 - 1759. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. S. Choi, Y. M. Shim, J. Kim, and K. Kim Mediastinoscopy in patients with clinical stage I non-small cell lung cancer Ann. Thorac. Surg., February 1, 2003; 75(2): 364 - 366. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Nagai, R. Tsuchiya, T. Mori, H. Tada, Y. Ichinose, T. Koike, and H. Kato A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209) J. Thorac. Cardiovasc. Surg., February 1, 2003; 125(2): 254 - 260. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Kostakoglu and S. J. Goldsmith 18F-FDG PET Evaluation of the Response to Therapy for Lymphoma and for Breast, Lung, and Colorectal Carcinoma J. Nucl. Med., February 1, 2003; 44(2): 224 - 239. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.G. Spiro Surgery for nonsmall cell lung cancer: can improvements be made? Eur. Respir. J., January 1, 2003; 21(39_suppl): 52S - 56s. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. S. Choi, Y. M. Shim, J. Kim, and K. Kim Recurrence-free survival and prognostic factors in resected pN2 non-small cell lung cancer Eur. J. Cardiothorac. Surg., November 1, 2002; 22(5): 695 - 700. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. G. Spiro and J. C. Porter Lung Cancer--Where Are We Today?: Current Advances in Staging and Nonsurgical Treatment Am. J. Respir. Crit. Care Med., November 1, 2002; 166(9): 1166 - 1196. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Cyjon, M. Nili, G. Fink, M. R. Kramer, E. Fenig, J. Sandbank, A. Sulkes, and E. Rakowsky Advanced non-small cell lung cancer: induction chemotherapy and chemoradiation before operation Ann. Thorac. Surg., August 1, 2002; 74(2): 342 - 347. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Raja, T. El-Hefnawy, L. A. Kelly, M. L. Chestney, J. D. Luketich, and T. E. Godfrey Temperature-controlled Primer Limit for Multiplexing of Rapid, Quantitative Reverse Transcription-PCR Assays: Application to Intraoperative Cancer Diagnostics Clin. Chem., August 1, 2002; 48(8): 1329 - 1337. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Martin, R. J. Ginsberg, E. S. Venkatraman, M. S. Bains, R. J. Downey, R. J. Korst, M. G. Kris, and V. W. Rusch Long-Term Results of Combined-Modality Therapy in Resectable Non-Small-Cell Lung Cancer J. Clin. Oncol., April 15, 2002; 20(8): 1989 - 1995. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.A. Verschakelen, J. Bogaert, and W. De Wever Computed tomography in staging for lung cancer Eur. Respir. J., February 1, 2002; 19(35_suppl): 40S - 48s. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.F. Vansteenkiste Imaging in lung cancer: positron emission tomography scan Eur. Respir. J., February 1, 2002; 19(35_suppl): 49S - 60s. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Deslauriers Current surgical treatment of nonsmall cell lung cancer 2001 Eur. Respir. J., February 1, 2002; 19(35_suppl): 61S - 70s. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. F. Esnaola, S. N. Lazarides, S. J. Mentzer, and K. M. Kuntz Outcomes and Cost-Effectiveness of Alternative Staging Strategies for Non-Small-Cell Lung Cancer J. Clin. Oncol., January 1, 2002; 20(1): 263 - 273. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Akhurst, R. J. Downey, M. S. Ginsberg, M. Gonen, M. Bains, R. Korst, R. J. Ginsberg, V. W. Rusch, and S. M. Larson An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer Ann. Thorac. Surg., January 1, 2002; 73(1): 259 - 266. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Voltolini, L. Luzzi, C. Ghiribelli, P. Paladini, M. Di Bisceglie, and G. Gotti Results of induction chemotherapy followed by surgical resection in patients with stage IIIA (N2) non-small cell lung cancer: the importance of the nodal down-staging after chemotherapy Eur. J. Cardiothorac. Surg., December 1, 2001; 20(6): 1106 - 1112. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Martin, R. J. Ginsberg, A. Abolhoda, M. S. Bains, R. J. Downey, R. J. Korst, T. L. Weigel, M. G. Kris, E. S. Venkatraman, and V. W. Rusch Morbidity and mortality after neoadjuvant therapy for lung cancer: the risks of right pneumonectomy Ann. Thorac. Surg., October 1, 2001; 72(4): 1149 - 1154. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.W. A. Oosterhuis, P. H.M.H. Theunissen, and E. C.M. Bollen Improved pre-operative mediastinal staging in non-small-cell lung cancer by serial sectioning and immunohistochemical staining of lymph-node biopsies Eur. J. Cardiothorac. Surg., August 1, 2001; 20(2): 335 - 338. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Doddoli, P. Thomas, X. Thirion, Y. Seree, R. Giudicelli, and P. Fuentes Postoperative complications in relation with induction therapy for lung cancer Eur. J. Cardiothorac. Surg., August 1, 2001; 20(2): 385 - 390. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Margaritora, A. Cesario, D. Galetta, A. D'Andrilli, G. Macis, G. Mantini, L. Trodella, and P. Granone Ten year experience with induction therapy in locally advanced non-small cell lung cancer (NSCLC): is clinical re-staging predictive of pathological staging? Eur. J. Cardiothorac. Surg., June 1, 2001; 19(6): 894 - 898. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.F. Vansteenkiste and S.G. Stroobants The role of positron emission tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory oncology Eur. Respir. J., April 1, 2001; 17(4): 802 - 820. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Bueno, W. G. Richards, S. J. Swanson, M. T. Jaklitsch, J. M. Lukanich, S. J. Mentzer, and D. J. Sugarbaker Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival Ann. Thorac. Surg., December 1, 2000; 70(6): 1826 - 1831. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Mateu-Navarro, R. Rami-Porta, R. Bastus-Piulats, L. Cirera-Nogueras, and G. Gonzalez-Pont Remediastinoscopy after induction chemotherapy in non-small cell lung cancer Ann. Thorac. Surg., August 1, 2000; 70(2): 391 - 395. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Van Zandwijk, E. F. Smit, G. W. P. Kramer, F. Schramel, S. Gans, J. Festen, A. Termeer, N. J. J. Schlosser, C. Debruyne, D. Curran, et al. Gemcitabine and Cisplatin as Induction Regimen for Patients With Biopsy-Proven Stage IIIA N2 Non-Small-Cell Lung Cancer: A Phase II Study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955) J. Clin. Oncol., July 14, 2000; 18(14): 2658 - 2664. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Okada, N. Tsubota, M. Yoshimura, Y. Miyamoto, and H. Matsuoka Induction Therapy for Non-small Cell Lung Cancer With Involved Mediastinal Nodes in Multiple Stations Chest, July 1, 2000; 118(1): 123 - 128. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Yamamoto, H. Tada, A. Kishi, and T. Tojo Effects of preoperative chemotherapy and radiation therapy on human bronchial blood flow J. Thorac. Cardiovasc. Surg., May 1, 2000; 119(5): 939 - 945. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M.W. Pisters, R. J. Ginsberg, D. J. Giroux, J. B. Putnam Jr, M. G. Kris, D. H. Johnson, J. R. Roberts, J. Mault, J. J. Crowley, and P. A. Bunn Jr INDUCTION CHEMOTHERAPY BEFORE SURGERY FOR EARLY-STAGE LUNG CANCER: A NOVEL APPROACH J. Thorac. Cardiovasc. Surg., March 1, 2000; 119(3): 429 - 439. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. White, S. Cheeseman, N. Thatcher, H. Anderson, B. Carrington, S. Hearn, G. Ross, and M. Ranson Phase II Study of Oral Topotecan in Advanced Non-Small Cell Lung Cancer Clin. Cancer Res., March 1, 2000; 6(3): 868 - 873. [Abstract] [Full Text] |
||||
![]() |
G. M. Strauss Role of Chemotherapy in Stages I to III Non-small Cell Lung Cancer* Chest, December 1, 1999; 116 (2009): 509S - 516S. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Naruke, R. Tsuchiya, H. Kondo, H. Nakayama, and H. Asamura Lymph node sampling in lung cancer: how should it be done? Eur. J. Cardiothorac. Surg., September 1, 1999; 16(suppl_1): S17 - S24. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Downey, N. Martini, V. W. Rusch, M. S. Bains, R. J. Korst, and R. J. Ginsberg Extent of chest wall invasion and survival in patients with lung cancer Ann. Thorac. Surg., July 1, 1999; 68(1): 188 - 193. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Suzuki, K. Nagai, J. Yoshida, M. Nishimura, K. Takahashi, and Y. Nishiwaki THE PROGNOSIS OF SURGICALLY RESECTED N2 NON-SMALL CELL LUNGCANCER: THE IMPORTANCE OF CLINICAL N STATUS J. Thorac. Cardiovasc. Surg., July 1, 1999; 118(1): 145 - 153. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. De Leyn, J. Vansteenkiste, G. Deneffe, D. Van Raemdonck, W. Coosemans, and T. Lerut Result of induction chemotherapy followed by surgery in patients with stage IIIA N2 NSCLC: importance of pre-treatment mediastinoscopy Eur. J. Cardiothorac. Surg., May 1, 1999; 15(5): 608 - 614. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Rendina, F. Venuta, T. D. Giacomo, A. M. Ciccone, G. Ruvolo, G. F. Coloni, C. Ricci, and S. G. A. Patterson INDUCTION CHEMOTHERAPY FOR T4 CENTRALLY LOCATED NON-SMALL CELL LUNG CANCER J. Thorac. Cardiovasc. Surg., February 1, 1999; 117(2): 225 - 233. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Leong, C. M. Rocha Lima, C. A. Sherman, and M. R. Green The 1997 International Staging System for Non-Small Cell Lung Cancer: Have All the Issues Been Addressed? Chest, January 1, 1999; 115(1): 242 - 248. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Vansteenkiste, P. De Leyn, G. Deneffe, J. Menten, T. Lerut, and M. Demedts Present status of induction treatment in stage IIIA-N2 non-small cell lung cancer: a review Eur. J. Cardiothorac. Surg., January 1, 1998; 13(1): 1 - 12. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Nakanishi, T. Osaki, K. Nakanishi, I. Yoshino, T. Yoshimatsu, H. Watanabe, H. Nakata, and K. Yasumoto Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer Ann. Thorac. Surg., August 1, 1997; 64(2): 342 - 348. [Abstract] [Full Text] |
||||
![]() |
J. D. Lee and R. J. Ginsberg Lung Cancer Staging: The Value of Ipsilateral Scalene Lymph Node Biopsy Performed at Mediastinoscopy Ann. Thorac. Surg., August 1, 1996; 62(2): 338 - 341. [Abstract] [Full Text] |
||||
![]() |
M. J. Edelman, D. R. Gandara, M. Roach III, and J. R. Benfield Multimodality Therapy in Stage III Non-Small Cell Lung Cancer Ann. Thorac. Surg., May 1, 1996; 61(5): 1564 - 1572. [Abstract] [Full Text] |
||||
![]() |
D. J. Mathisen, J. C. Wain, C. Wright, N. Choi, R. Carey, A. Hilgenberg, M. Grossbard, T. Lynch, and H. Grillo ASSESSMENT OF PREOPERATIVE ACCELERATED RADIOTHERAPY AND CHEMOTHERAPY IN STAGE IIIA (N2) NON-SMALL-CELL LUNG CANCER J. Thorac. Cardiovasc. Surg., January 1, 1996; 111(1): 123 - 133. [Abstract] [Full Text] |
||||
![]() |
D. J. Sugarbaker, J. Herndon, L. J. Kohman, M. J. Krasna, M. R. Green, t. C. a. L. G. B T. S. Group, and S. b. V. Rusch Results of cancer and leukemia group B protocol 8935A multiinstitutional phase II trimodality trial for stage IIIa (N2) non-small-cell lung cancer J. Thorac. Cardiovasc. Surg., March 1, 1995; 109(3): 473 - 485. [Abstract] [Full Text] |
||||
![]() |
V. Cocquyt, W. De Neve, S. J.-P. Van Belle, N. Chanarin, N. E. Mills, C. L. Fishman, D. R. Jacobson, S.-A. McLachlan, M. Stockler, and R. Rosell Chemotherapy plus Surgery versus Surgery Alone in Non-Small-Cell Lung Cancer N. Engl. J. Med., June 16, 1994; 330(24): 1756 - 1757. [Full Text] |
||||
![]() |
R. Rosell, J. Gomez-Codina, C. Camps, J. Maestre, J. Padille, A. Canto, J. L. Mate, S. Li, J. Roig, A. Olazabal, et al. A Randomized Trial Comparing Preoperative Chemotherapy Plus Surgery with Surgery Alone in Patients with Non-Small-Cell Lung Cancer N. Engl. J. Med., January 20, 1994; 330(3): 153 - 158. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |